NSCLC: State of the Art Diagnosis, Treatment, and Outcomes

Abstract

Lung cancer is the major cause of cancer mortality in the USA. In this review, we aim to provide a general update on the current status of non-small cell lung cancer (NSCLC) management. Novel approaches in the diagnosis and treatment of non-small cell lung cancer have been made recently and this was revolutionary in the way lung cancer management has changed even-though the improvement in overall survival remains modest. Furthermore, lung cancer screening using low-dose computed tomography scan has shown benefit in high-risk populations. The diagnosis of lung cancer has evolved over the last couple of years with the new endoscopic modalities. Targeted therapies and immunotherapies, including tyrosine kinase inhibitors and checkpoint inhibitors, constitutes the current progress made in the treatment of lung cancer, and have helped improve survival in the metastatic setting. Many trials are ongoing in investigating other biomarkers.